Active Filter(s):
Details:
SYN117 (nepicastat), is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda’s U.S. subsidiary, Biotie Therapies, Inc.
Lead Product(s): Nepicastat
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Asieris Pharmaceuticals
Deal Size: $7.5 million Upfront Cash: $0.5 million
Deal Type: Licensing Agreement August 29, 2022